13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
31 檔
34.1%
The Q1 2025 SEC filing reveals that Commodore Capital LP held a total portfolio value of $1.7B, covering 31 public equity positions.
Commodore Capital LP executed strategic sector rebalancing during Q1 2025, establishing 26 new positions while fully exiting 24 holdings and trimming 1 positions.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, NUVL, ELVN) accounted for 34.1% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 13.87% | — | +15.45% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 9.69% | -4.20% | +14.39% | |
| 3 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.78% | +2.47% | +11.18% | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.05% | -1.26% | EXIT | |
| 5 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.75% | -2.78% | EXIT | |
| 6 | ALKS | Alkermes plc | Stock-Healthcare | 4.74% | +0.77% | -15.22% | |
| 7 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 4.72% | — | — | |
| 8 | PCVX | Vaxcyte Inc | Stock-Other | 4.59% | — | +1.54% | |
| 9 | VERA | Vera Therapeutics Inc | Stock-Other | 4.53% | — | +30.80% | |
| 10 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.28% | -1.96% | — | |
| 11 | SRRK | Scholar Rock Holding CORP | Stock-Other | 4.13% | — | +83.68% | |
| 12 | COGT | Cogent Biosciences Inc | Stock-Other | 3.93% | +0.60% | +29.23% | |
| 13 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.58% | — | +50.00% | |
| 14 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.48% | -2.04% | EXIT | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.51% | — | +6.72% | |
| 16 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.36% | -1.10% | — | |
| 17 | PHVS | Pharvaris N.V. | Stock-Other | 2.21% | -0.21% | — | |
| 18 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.95% | — | +5.03% | |
| 19 | SLDB | Solid Biosciences Inc | Stock-Other | 1.59% | — | — | |
| 20 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.33% | — | — | |
| 21 | CRDF | Cardiff Oncology Inc | Stock-Other | 1.25% | — | — | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.07% | — | — | |
| 23 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.86% | +0.13% | -9.80% | |
| 24 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.82% | — | — | |
| 25 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.80% | — | — | |
| 26 | NGNE | Neurogene Inc | Stock-Other | 0.80% | — | +15.63% | |
| 27 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.65% | -1.91% | — | |
| 28 | ✓ | Stock-Other | 0.57% | — | — | ||
| 29 | CELC | Celcuity Inc | Stock-Other | 0.52% | — | +73.91% | |
| 30 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.29% | +0.04% | NEW | |
| 31 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.29% | +0.70% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XENE | Xenon Pharmaceuticals Inc | +3.7% | -15.15% | Add |
| 2 | VRDN | Viridian Therapeutics Inc | +1.3% | +50.00% | Add |
| 3 | CLDX | Celldex Therapeutics Inc | +0.6% | — | Add |
| 4 | COGT | Cogent Biosciences Inc | +0.1% | +29.23% | Add |
| 5 | CELC | Celcuity Inc | -6.7% | +73.91% | Trim |
| 6 | ✓ | Merus N V | — | NEW | New buy |
| 7 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 8 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 9 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 10 | ALKS | Alkermes plc | — | NEW | New buy |
| 11 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 12 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 13 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 14 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 15 | NRIX | Nurix Therapeutics Inc | — | NEW | New buy |
| 16 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 17 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 18 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 19 | ACRS | Aclaris Therapeutics Inc | — | EXIT | Sold out |
| 20 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 21 | STSAUSD | Satsuma Pharmaceuticals Inc | — | EXIT | Sold out |
| 22 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 23 | CCCC | C4 Therapeutics Inc | — | EXIT | Sold out |
| 24 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 25 | CRDF | Cardiff Oncology Inc | — | NEW | New buy |
| 26 | CBAYUSD | Cymabay Therapeutics Inc | — | EXIT | Sold out |
| 27 | CNST | Constellation Pharmaceutical | — | EXIT | Sold out |
| 28 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 29 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 30 | KURA | Kura Oncology Inc | — | EXIT | Sold out |
| 31 | IKT | Inhibikase Therapeutics Inc | — | NEW | New buy |
| 32 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 33 | OPHTEUR | Iveric Bio Inc | — | EXIT | Sold out |
| 34 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 35 | NGNE | Neurogene Inc | — | NEW | New buy |
| 36 | MGNX | Macrogenics Inc | — | EXIT | Sold out |
| 37 | VTGNUSD | Vistagen Therapeutics Inc | — | EXIT | Sold out |
| 38 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 39 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 40 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 41 | ✓ | — | NEW | New buy | |
| 42 | KRON1USD | Kronos Bio Inc | — | EXIT | Sold out |
| 43 | GNCAQ | Genocea Biosciences Inc | — | EXIT | Sold out |
| 44 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 45 | DYN | Dyne Therapeutics Inc | — | EXIT | Sold out |
| 46 | ✓ | Mersana Therapeutics Inc | — | EXIT | Sold out |
| 47 | 4XC1 | Kalvista Pharmaceuticals Inc | — | EXIT | Sold out |
| 48 | PMVP | Pmv Pharmaceuticals Inc | — | EXIT | Sold out |
| 49 | VTGN | Vistagen Therapeutics Inc | — | NEW | New buy |
| 50 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 31 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MERUS N V
市值: $188.3M
Top Position Liquidated / Trimmed
ACRS
前期市值: $29.3M
During Q1 2025, Commodore Capital LP's top holdings by market value included MERUS N V (13.9%)、NUVL (9.7%)、ELVN (6.8%). The largest single position, MERUS N V, represented 13.9% of total portfolio value.
In Q1 2025, Commodore Capital LP made 55 total portfolio adjustments, initiating 26 new buys, adding to 4 positions, trimming 1 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.